Skip to main content
Uncategorized

Advancell and ISDIN collaborate in research and development of new nanomedical treatments in dermatology

By 6 de October de 2006November 18th, 2020No Comments
< Back to news
 06.10.2006

Advancell and ISDIN collaborate in research and development of new nanomedical treatments in dermatology

Source: Advancell
, a company specialized in biotech research, and , a leading Spanish laboratory in dermatological products, have signed a framework collaboration agreement for the development of innovative nanomedicines for the treatment of skin diseases. The extensive experience of ISDIN in the field of dermatology together with the technology developed by Advancell in the use of natural polymers for drug delivery will allow skin disorders to be treated with greater efficacy and less toxicity through the development of new pharmaceutical agents. In addition, current treatments will be improved by providing new and more efficient methods of application.

In its first phase, research will focus on the treatment of atopic dermatitis and psoriasis. The goal is to launch new drugs onto the market in 2012.

Advancell’s technology derives from research developed by the Universitat de Santiago de Compostela since 1995 on certain natural polymers, which, in combination with drugs, produce nanometric scale structures that allow drugs to be administered in a non-classical way. The potential of this technology is particularly important in the field of dermatology since it will facilitate the external use of certain drugs, thereby achieving greater treatment efficacy.

Luis Ruiz, director of Advancell, has pointed out that “the agreement corroborates the potential of our technology since ISDIN, specialized in dermatology, has placed its trust in our expertise for the development of its drugs. This is a great opportunity for Advancell since it promotes our business model and validates our technological base”. For ISDIN, the collaboration agreement with Advancell reinforces its commitment to research and represents another step towards the development of new formulations that contribute to the treatment of skin problems and to improving patients’ quality of life.